



Journal of Enzyme Inhibition and Medicinal Chemistry

ISSN: 1475-6366 (Print) 1475-6374 (Online) Journal homepage: http://www.tandfonline.com/loi/ienz20

Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds

Susanna Nencetti, Lidia Ciccone, Armando Rossello, Elisa Nuti, Claudio Milanese & Elisabetta Orlandini

To cite this article: Susanna Nencetti, Lidia Ciccone, Armando Rossello, Elisa Nuti, Claudio Milanese & Elisabetta Orlandini (2015) Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalenmethylsulfonamido compounds, Journal of Enzyme Inhibition and Medicinal Chemistry, 30:3, 406-412, DOI: <u>10.3109/14756366.2014.940937</u>

To link to this article: http://dx.doi.org/10.3109/14756366.2014.940937



Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=ienz20

Journal of Enzyme Inhibition and Medicinal Chemistry

http://informahealthcare.com/enz ISSN: 1475-6366 (print), 1475-6374 (electronic)

J Enzyme Inhib Med Chem, 2015; 30(3): 406–412 © 2014 Informa UK Ltd. DOI: 10.3109/14756366.2014.940937

RESEARCH ARTICLE

Synthesis and cycloxygenase inhibitory properties of new naphthalene-methylsulfonamido, naphthalene-methylsulfonyl and tetrahydronaphthalen-methylsulfonamido compounds

Susanna Nencetti¹, Lidia Ciccone¹, Armando Rossello¹, Elisa Nuti¹, Claudio Milanese², and Elisabetta Orlandini¹

¹Dipartimento di Farmacia, Università Pisa Via Bonanno, Pisa, Italy and ²A.C.R.A.F. S.p.A. – Angelini Research Center, P.le della Stazione snc, S.N- Palomba- Pomezia, Rome, Italy

Abstract

We synthesized a series of new naphthalene derivatives: naproxen- and 6-methoxy naphthalene acetic acid-like **1–5**. In these compounds the carboxylic function, typical of the classical NSAIDs, was replaced by a methylsulfonamido (**1**, **2** and **6a–c**) or methylsulfonyl (**3–5**) group present in some selective COX-2 inhibitors. We also synthesized compounds **7** and **8** in which the naphthalene portion was substituted by tetrahydronaphthalene ring. Some of the new compounds were assayed for their enzymatic inhibitory activity towards cycloxygenase enzymes. Compounds **4** and **6b**, at a concentration of 10 μ M exhibit percentage inhibition values of 65%, 50% and 29%, 87% towards COX-2 and COX-1, respectively. The substitution of carboxylic group with a mehylsulfonamido or a methylsulfonyl groups does not allow to direct the selectivity versus to cycloxygenase enzymes.

Keywords

Cycloxygenase inhibitors, naphthalene derivatives, naphthalene-methylsulfonamido compounds, naphthalenemethylsulfonyl compounds, tetrahydronaphthalenmethylsulfonamido compounds

informa

healthcare

History

Received 23 May 2014 Revised 23 June 2014 Accepted 23 June 2014 Published online 29 July 2014

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are competitive inhibitors of the cycloxygenase (COX) enzymes. These enzymes exist in two isoforms: COX-1, which is constitutive, and COX-2 which is inducible. COX-1 is expressed in the most of tissues and is involved in physiological production of PGs responsible of gastric cytoprotection, COX-2 in normal conditions has lower expression levels in tissues, but its expression is increased during inflammatory responses. The up-regulation of COX-2 was also observed in premalignant and malignant conditions of various cancers such as breast, prostate and lung ones which metastasize in the bones¹. Particular attention has been recently focused on the role that COX-2 enzyme could play in Alzheimer's diseases (AD)^{2,3}.

After the removal from the market of some selective COX-2 inhibitors (COXIBs), due to their cardiovascular side effects, the research has focused towards the evaluation of alternative chemical structures able to maintain the COX inhibitory activity with reduced side effects⁴.

With this aim, we synthesized a series of new naphthalene derivatives naproxene and 6-methoxy naphthalene acetic acid-like (6-MNA; 1–6; Figure 1). In these compounds, the carboxylic function, typical of the classical NSAIDs, was replaced by a

Address for correspondence: Elisabetta Orlandini, Dipartimento di Farmacia, Università Pisa, Via Bonanno 6, 56126 Pisa, Italy. E-mail: elisabetta.orlandini@farm.unipi.it

methylsulfonamido (1, 2, 6a-c) or methylsulfonyl (3-5) group present in some selective COX-2 inhibitors as for example NS398 or SC-57666, respectively. We also synthesized the methylsulfonamido compounds 7 and 8 in which the naphthalene portion was substituted by tetrahydronaphthalene ring.

Methods

Chemistry

The synthesis of compounds 1 and 2 were carried out as depicted in Schemes 1 and 2.

The isocyanate **8**, obtained according to the synthetic method reported in literature⁵, treated with trifluoroacetic acid in methylene chloride gave the 2,2,2-trifluoro-N-[1-(6-methoxy-naphthalen-2-yl)-ethyl]-acetamide **9**. Compound **9** by hydrolysis with potassium carbonate in aqueous methanol afforded the amine **10**. By reaction of the derivative **10**, with mesyl chloride and triethylamine, we obtained the desired compound **1**.

The N-(6-Methoxy-naphthalen-2-ylmethyl)-methanesulfonamide **2** was prepared as shown in Scheme 2. The catalytic hydrogenation with Pd/C in acid medium of the commercial available 6-methoxy-naphthalene-2-carbonitrile **11** afforded the amine **12**, which by subsequent treatment with mesyl chloride and triethylamine furnished the compound **2**.

The synthesis of the compounds 3 and 4 are shown in Schemes 3 and 4.

The reduction of the commercial available 1-(6-methoxy-naphthalen-2-yl) ethanone 13 with NaBH₄ afforded the alcohol⁶



Figure 1. General structure of NS398 and SC5766, 6-MNA, naproxene and new naphthalene 1-6 and tetrahydronaphthalene 7 and 8 compounds.



a: CF₃COOH, CH₂Cl₂; b: K₂CO₃, H₂O/MeOH; c: CH₃SO₂Cl, NEt₃, CH₂Cl₂

Scheme 1.



a: H₂, Pd/C, H⁺; b: CH₃SO₂Cl, NEt₃, CH₂Cl₂

Scheme 2.



a: NaBH₄; MeOH; b: BF₃·Et₂O, NaI, CH₃CN; c: CH₃SO₂Na, (C₄H₉)₄N⁺Br⁻ DMF 80 °C, 48 h



a: DIBALH, benzene, 2h, 5 °C; b: BF ₃.Et₂O, Nal, CH₃CN; c: CH₃SO₂Na, (C₄H₉)₄N⁺Br⁻, DMF, 80 °C, 48h

Scheme 4.

a: CF₃COOH, CH₂Cl₂; b: K₂CO₃, H₂O/MeOH; c: CH₃SO₂Cl, Pyr, CH₂Cl₂

Scheme 5.



a: R= H, b:R= CI ; c: R= Br

a: SOCl₂, 3h; b: AlCl₃; c: NH₂NH₂.H₂O, Ni/Raney, EtOH; d: CH₃SO₂Cl, Pyr, CH₂Cl₂

Scheme 6.

14 which was transformed in the corresponding iodine derivative 15. The treatment of compound 15 with the sodium salt of methane sulfinic acid in presence of tetrabutylammoniumbromide afforded the methylsulfone 3.

Commercially available 6-Methoxy-naphthalene-2-aldehyde **16** was reduced with diisobutylaluminum hydride to afford the corresponding alcohol **17**. Compound **17** by treatment with NaI and $BF_3 \cdot Et_2O$ afforded the corresponding iodine derivative **18**. The desidered methylsulfone **4** was obtained by treatment with the sodium salt of methane sulfinic acid of the iodine derivative **18**.

Compound **5** was obtained as reported in Scheme 5. The 6-Methoxynaphthylisocyanate **19**⁷, prepared from commercially available 6-methoxy-2-naphthoic acid by Curtius rearrangement of the corresponding acyl azide, in the presence of trifluoroacetic acid and methylene chloride, gave the 2,2,2-Trifluoro-N-(6-methoxy-naphthalen-2-yl)-acetamide **20**, which by hydrolysis with potassium carbonate in aqueous methanol afforded the desidered amine **21**. Compound **21** treated with mesyl chloride and pyridine, furnished the desired compound **5**.

The general synthetic approach to compounds **6a–c** is outlined in Scheme 6. Compound **22** obtained according to the synthetic method reported in literature⁸ was treated by thionyl chloride to obtain the corresponding acid chloride **23**⁸. Compound **23** treated with the appropriate benzenic derivatives **24a–c** in AlCl₃ afforded the 2-nitro-4-benzoyl-naphthalene derivatives **25a–c**. Compounds **25a–c** have been reduced by hydrazine hydrate and Ni/Raney to the corresponding amines **26a–c**, and then treated with mesyl chloride and pyridine to give the desired derivatives **6a–c**.

The synthesis of methylsulfonamides 7 and 8 were reported in Scheme 7. The catalytic hydrogenation of 6-methoxy-3,4dihydro-(1,2)-naphtoquinone-2-oxime **27** with Pd/C in acid medium and the reduction of 7-methoxy-3,4-dihydro-1H-naphthalen-2-one **30** provided the amines **28**, **29**. The amines **28** and **29** treated with mesyl chloride and triethylamine furnished the desired compunds **7** and **8**.

Biological results and conclusion

For the new compounds **1–4**, **6a–b** and **7** the inhibitory activity towards COX-1 and COX-2 was evaluated *in vitro* by measuring the PGE2 production on activated J774.2 macrophages⁹. The results are reported in Table 1 together with those obtained in the same type of test with NS398 as reference drug.

Compounds 4 and 6b at a concentration of 10μ M exhibit percentage inhibition values of 65% and 50% toward COX-2 and 29% and 87% toward COX-1, while the other compounds resulted practically inactive. However, it can be seen how similar structures have completely different activity values as shown in Table 1 for compounds naproxene-like 2 (0, 13%) and 4 (29%, 65%). These data seem to indicate that in the class of the naproxene analogues 1–4 only the methylsulfonyl group, in substitution of the carboxylic function, is suitable for the interaction towards COX-2.

Regarding the compounds **6a–b** the introduction of a chlorine substituent on the benzoyl group (**6b**) confers a good inhibitory activity even if, no COX-1 and COX-2 selectivity, with respect to the unsubstituted analogue **6a** completely devoid of any cycloxygenase inhibitory activity. In this class of compounds would seem confirmed the observation that had already been highlighted for other class of antiinflammatory drugs, namely that the presence of a halogen on the benzoyl group is able to have a positive influence on the activity.



a: H₂, Pd/C, H⁺; b: CH₃SO₂Cl, NEt₃, CH₂Cl₂; c: CH₃COONH₄, NaBH₃CN, MeOH

Scheme 7.

Table 1. Biological data of compounds 1-4, 6a,b and 7.

Compound	% inhibition PGE2 ^a (10 µM)	
	COX-1	COX-2
1	0	2.5
2	0	13
3	0	0
4	29	65
6a	0	0
6b	87	50
7	18	7
NS398	59	80

^aSee Ref⁹

Experimental procedures

Chemistry

Analytical grade reagents and solvent were purchased from Sigma-Aldrich (St. Louis, MO), and were used as supplied. Solvents were dried according to standard methods. All chemical reactions were monitored by thin layer chromatography (TLC) using alumina plates coated with silica gel 60 F254 (Merck, Darmstadt, Germany) containing a fluorescent indicator; spots were detected under UV light (254 nm). Column flash chromatography separations were performed on silica gel Merck 230–400 mesh ASTM Evaporations were made *in vacuo* (rotating evaporator); Na₂SO₄ was always used as the drying agent. Melting points were determined by a Kofler apparatus (A) and are uncorrected. IR spectra for comparison of compounds were taken as paraffin oil mulls or as liquid films on a Unicam Mattson 1000 FT-IR spectrometer (Cambridge, UK). ¹H-NMR spectra were obtained with a Varian Gemini CTF 20 spectrometer (Mountain View, CA) operating at 80 MHz, at 25 °C in ca. 5% solution of CDCl₃. Chemical shifts (δ) are reported in ppm, coupling constants J are reported in Hertz. The following abbreviations are used: singlet (s), doublet (d), triplet (t), broad singlet (bs) and multiplet (m). Elemental analyses were performed in our analytic laboratory and agree with the theoretical values to within $\pm 0.4\%$. Mass spectrometry data were collected by spectrophotometer Hewelett Packard 5988A (Palo Alto, CA) by direct introduction at a nominal electron energy of 70 eV and a source temperature at 350 °C.

2,2,2-Trifluoro-N-[1-(6-methoxynaphthalen-2-yl)-ethyl]-acetamide (9)

To a solution of 2-(1-Isocyanato-ethyl)-6-methoxynaphthalene 8 (384 mg, 1.69 mmol) in CH₂Cl₂ (15 ml) was added dropwise

trifluoroacetic acid (0.175 ml, 2.28 mmol). After 10 h at reflux temperature, the mixture was cooled at room temperature and then washed with a solution of NaHCO₃, dried and filtered to give **9**. Yield 84%; m.p.: 175–180 °C; IR (ν , cm⁻¹): 3335 (NH), 1700 (C=O); ¹H-NMR δ : 7.82–7.11 (m, 6H, aromatic-H), 4.85–4.78 (m, 1H, CH), 3.9 (s, 3H, CH₃O), 1.85 (bs, 1H, NH), 1.43 (d, 3H, J= 6.4 Hz, CH₃); MS: 297 (M⁺, 30), 185 (100); Anal. Calcd. for C₁₅H₁₄ F₃NO₂ (297.27): C, 60.60; H, 4.75; N, 4.71%. Found: C, 61.00; H, 5.07; N, 4.32%.

1-(6-Methoxynaphthalen-2-yl)-ethylamine (10)

To a solution of 2,2,2-trifluoro-N-[1-(6-methoxynaphthalen-2-yl)ethyl]-acetamide (9) (331 mg, 1.11 mmol) in MeOH (20 ml) was added a solution of K₂CO₃ (255 mg, 1.85 mmol) in H₂O/MeOH (1:1, 5 ml). The resulting mixture was stirred at room temperature for 48 h, then the solvent was evaporated and the crude residue was dissolved in CH2Cl2, extracted with HCl 5%, alkalized, and finally extracted with AcOEt. The organic phase was then dried, filtered and evaporated, to give an oily residue, which was purified by transformation in the corresponding hydrochloride salt, and crystallised from Et₂O/HCl. The hydrochloride salt of 10 was converted into a free base by treating an aqueous solution of the salt with solid KOH and extracting the free base with CHCl₃. The organic layer was washed (H₂O) filtered and evaporated to give **10** as a solid. **10**: Yield 64%; m.p.: 77–78 °C; ¹H-NMR δ : 7.72–7.06 (m, 6H, Ar), 4.3 (m, 1H, CH), 3.89 (s, 3H, CH₃O), 2.5 (bs, 1H, NH), 1.54 (d, 3H, J = 6.4 Hz, CH₃); MS: 201 (M⁺, 18), 186 (100); Anal. Calcd. for C₁₃H₁₅NO (201.26): C, 77.58; H, 7.51; N, 6.96%. Found: C, 77.13; H, 7.34; N, 6.98%.

(6-Methoxynaphthalen-2-yl)-methylamine (12)

A solution of 6-methoxynaphthalene-2-carbonitrile **11** (1 g, 5.46 mmol) in CHCl₃ (10 ml), absolute EtOH (20 ml) and 37%HCl (1 ml) was hydrogenated for 24 h in presence of Pd/C (400 mg). The catalyst was removed by filtration. The evaporation of the ethanolic solution provided **12** as hydrochloride which was crystallized from MeOH/Et₂O. **12**: Yield 81%, m.p.: 236–240 °C; IR (ν , cm⁻¹): 2654 (NH₂); ¹H-NMR (D₂O) δ : 7.90–7.23 (m, 6H, Ar), 4.05 (m, 2H, CH₂), 3.96 (s, 3H, CH₃O); MS: 187 (M⁺, 100), 171 (38); Anal. Calcd. for C₁₂H₁₃NO•HCl (223.63) C, 64.43; H, 6.31; N, 6.26%. Found: C, 64.05; H, 5.96; N, 6.10%.

N-[1-(6-Methoxynaphthalen-2-yl)-ethyl]methanesulfonamide (1) and N-(6Methoxynaphthalen-2-yl)methyl)-methanesulfonamide (2)

To a solution of appropriate hydrochloride salts of **10**, **12** (0.72 mmol) and NEt₃ (0.2 ml, 1.44 mmol) in anhydrous CH_2Cl_2 (8 ml) at 0 °C, was added dropwise CH_3SO_2Cl (0.056 ml,

410 S. Nencetti et al.

0.72 mmol). The mixture was stirred for 3 h at room temperature and after evaporated. The residue was dissolved in CH₂Cl₂, washed with 5% HCl and H2O. The organic phase was dried over anhydrous Na₂SO₄, and the solvent evaporated to afford the methansulfonamides 1 and 2 which were crystallized by CHCl₃/hexane. 1: Yield 69%; m.p.: 154–155 °C; IR (ν , cm⁻¹): 3227 (NH); ¹H-NMR δ: 7.77–7.09 (m, 6H, Ar), 4.73–4.65 (m, 1H, CH), 3.90 (s, 3H, CH₃SO₂), 1.57 (s, 1H, NH), 1.54 (d, 3H, $J = 6.4 \text{ Hz}, \text{ CH}_3$; MS: 281 (M+2, 1), 280 (M+1, 2), 279 (M⁺, 20), 185 (100); Anal. Calcd. for C₁₄H₁₇NO₃S (279.35) C, 60.19; H, 6.13; N, 5.01%. Found: C, 59.90; H, 6.06; N, 4.99%. 2: yield 75%; m.p.: 174–175 °C; IR (ν , cm⁻¹): 3246 (NH); ¹H-NMR δ : 7.85–7.05 (m, 6H, Ar), 4.32–4.24 (d, 2H, J=6.4 Hz, CH₂), 3.88 (s, 3H, CH₃O), 2.95 (s, 3H, CH₃SO₂); MS: 267 (M+2, 1), 266 (M+1, 3), 265 (M⁺, 28), 185 (100); Anal. Calcd. for C₁₃H₁₅NO₃S (265.33) C, 58.85; H, 5.70; N, 5.28%. Found: C, 59.11; H, 5.93; N, 5.14%.

1-(6-Methoxynaphthalen-2-yl)-ethanol (14)

To a solution of 1-(6-methoxynaphthalen-2-yl)-ethanone **13** (500 mg, 2.5 mmol) in MeOH (20 ml) was added NaBH₄ (277 mg, 7.5 mmol). The reaction mixture was stirred for 8 h, at r.t then evaporated at reduced pressure. The residue, dissolved in Et₂O/CH₂Cl₂ (1:1), was washed with H₂O, 10% HCl and with a saturated solution of NaCl. The organic phase was dried over anhydrous Na₂SO₄ and after evaporated. The residue obtained, crystallized from hexane afforded the pure compound **14. 14**: Yield 55%; m.p.: 113–114 °C⁶; IR (ν , cm⁻¹): 3338 (OH); ¹H-NMR δ : 7.74–7.07 (m, 6H, Ar), 4.97–5.04 (m, 1H, CH), 3.90 (s, 3H, CH₃O), 1.87 (s, 1H, OH), 1.56 (d, 3H, J = 6.4 Hz, CH₃); MS: 202 (M⁺, 54), 144 (100); Anal. Calcd. for C₁₃H₁₄O₂ (202.10) C, 77.20; H, 6.98%. Found: C, 77.05; H, 6.83%.

(6-Methoxynaphthalen-2-yl)-methanol (17)

A solution of 1-(6-Methoxynaphthalen-2-yl)-ethanone **16** (800 mg, 4.3 mmol) in benzene anhydrous, cooled at 0–5 °C, was added slowly dropwise under N₂ atmosphere DIBALH (6.45 mmol). The reaction mixture was stirred at 5 °C for 2 h, than was quenched with MeOH excess. Aluminum salts were removed by filtration and washed with warm MeOH; the filtrate was evaporated under reduced pressure. The crude product crystallized by CH₂Cl₂/hexane, gave pure **17**. **17**: Yield 81%; m.p.: 116–118 °C; IR (ν , cm⁻¹): 3261 (OH); ¹H-NMR δ : 7.74–7.04 (m, 6H, Ar), 4.78 (s, 2H, CH₂), 3.89 (s, 3H, CH₃O); MS: 188 (M⁺, 100), 115 (80); Anal. Calcd. for C₁₂H₁₂O₂ (188.08) C, 76.57; H, 6.43%. Found: C, 76.19; H, 6.81%.

2-(1-lodo-ethyl)-6-methoxynaphthalene (15) and 2-lodomethyl-6-methoxynaphthalene (18)

To a solution of appropriate alcohol **14**, **17** (3.19 mmol) and NaI (957 mg, 6.38 mmol) in anhydrous CH₃CN (25 ml) was added dropwise, in 15 minutes, BF₃ Et₂O freshly distilled (9.57 mmol). The reaction mixture was stirred for 5 h (for compound **15**) and for 45 minutes (for compound **18**), then the organic phase was treated with brine (30 ml), a solution of 15% Na₂S₂O₃ and finally extracted with Et₂O. Ether phase washed with H₂O and with saturated solution of NaCl, dried and evaporated afforded the iodine derivatives **15** and **18** which were crystallized by hexane and AcOEt/hexane, respectively. **15**: Yield 46%; ¹H-NMR δ : 7.71–7.01 (m, 6H, Ar), 4.73–4.65 (m, 1H, CH), 3.91 (s, 3H, CH₃O), 1.63 (d, 3H, J = 6.4Hz, CH₃); MS: 186 (M+-I); Anal. Calcd. for C₁₃H₁₃IO (312.15) C, 52.02; H, 4.20%. Found: C, 52.34; H, 4.36%. **18**: Yield 32%; ¹H-NMR δ : 7.69–7.05 (m, 6H, Ar), 4.60 (s, 2H, CH₂), 3.89 (s, 3H, CH₃O); MS: 171 (M⁺-I, 100),

128(80); Anal. Calcd. for $C_{12}H_{11}IO$ (298.12) C, 48.35; H, 3.72%. Found: C, 48.60; H, 4.01%.

2-(1-Methanesulfonyl-ethyl)-6-methoxynaphthalene (3) and 2-Methanesulfonylmethyl-6-methoxynaphthalene (4)

A solution of the appropriate iodine derivatives 15, 18 (1.04 mmol), CH₃SO₂Na (111 mg, 1.09 mmol), tetrabutylammoniumbromide (351 mg, 1.09 mmol) in anhydrous DMF (8 ml) was stirred at 80 °C for 48 h. After, the reaction mixture was treated with H₂O/ice and extracted with CHCl₃. The organic phase, washed with H₂O, dried, evaporated under reduced pressure, afforded the derivatives 3 and 4 which were crystallized by CHCl₃/hexane. **3**: Yield 42%; ¹H-NMR δ: 7.71–7.01 (m, 6H, Ar), 4.85–4.75 (m, 1H, CH), 3.9 (s, 3H, CH₃O), 2.74 (s, 3H, CH₃SO₂), 1.43 (d, 3H, J = 6.4 Hz, CH₃); MS: 265 (M+1, 0.67), 264 (M+, 3), 185 (100); Anal. Calcd. for C₁₄H₁₆O₃S (264.34) C, 63.61; H, 6.10%. Found: C, 63.26; H, 6.45%. 4: Yield 60%; m.p.: 148 °C, ¹H-NMR δ : 7.76-7.10 (m, 6H, Ar), 4.35 (s, 2H, CH₂), 3.91 (s, 3H, CH₃O), 2.74 (s, 3H, CH₃SO₂); MS: 251 (M+1, 1), 250 (M⁺, 2), 171 (100); Anal. Calcd. for C₁₃H₁₄O₃S (250.31) C, 62.38; H, 5.64%. Found: C, 61.99; H, 5.82%.

2,2,2-Trifluoro-N-(6-methoxynaphthalen-2-yl)acetamide (20)

To a solution of 2-Isocyanato-6-methoxynaphthalene **19** (337 mg, 1.69 mmol) in CH₂Cl₂ (15 ml) was added dropwise trifluoroacetic acid (0.175 ml, 2.28 mmol). The reaction mixture was refluxed at 40 °C under stirring for 48 h. The organic solution cooled, washed with NaHCO₃, dried and evaporated under reduced pressure gave pure **20**. **20**: Yield 70%; m.p.: 132–140 °C, IR (ν , cm⁻¹): 3275 (NH), 1703 (C=O); ¹H-NMR δ : 7.96–7.45 (m, 6H, Ar), 3.90 (s, 3H, CH₃O); MS: 269 (M⁺, 100); Anal. Calcd. for C₁₃H₁₀F₃NO₂ (269.22) C, 58.00; H, 3.74; N, 5.20%. Found: C, 58.33; H, 4.03; N, 4.85%.

6-Methoxynaphthalen-2-ylamine (21)

To a solution of 2,2,2-Trifluoro-N-(6-methoxynaphthalen-2-yl)acetamide 20 (300 mg, 1.85 mmol) in MeOH (20 ml) was added a solution of K₂CO₃ (225 mg, 1.85 mmol) in H₂O/MeOH (1:1, 5 ml). The mixture was stirred at 40 °C for 48 h, then evaporated under reduced pressure. The residue was dissolved in CH₂Cl₂ extracted with HCl 5%, alkalized, and finally extracted with AcOEt. The organic phase, dried and evaporated under reduced pressure, gave 21 which in presence of Et₂O/HCl was transformed into the corresponding hydrochloride. The hydrochloride salt of 20 was converted into a free base by treating an aqueous solution of the salt with solid KOH and extracting the free base with CHCl₃ the organic layer was washed (H₂O) filtered and evaporated to give 21 as a solid. 21:Yield 80%; m.p.: 241-245 °C, IR (ν , cm⁻¹): 3384 (NH₂), 1703 (C=O); ¹H-NMR δ : 7.81–7.33 (m, 6H, Ar), 3.90 (s, 3H, CH₃O), 2.45 (bs, 1H, NH₂); MS: 173 (M⁺, 72), 158 (82), 130 (100); Anal. Calcd. for C₁₁H₁₁NO (173.31) C, 76.28; H, 6.40; N, 8.09%. Found: C, 75.90; H, 6.70; N, 8.10%.

N-(6-Methoxynaphthalen-2-yl)-methanesulfonamide (5)

To a solution of 6-methoxynaphthalen-2-ylamine **21** (123 mg, 0.71 mmol), pyridine (0.114 ml, 1.42 mmol) in anhydrous CH_2Cl_2 (8 ml), cooled at 0°C, CH_3SO_2Cl (0.055 ml, 0.71 mmol) was added dropwise. The mixture was stirred for 2 h at room temperature, evaporated under reduced pressure. The residue obtained was dissolved in CHCl₃, washed with H_2O and 5% HCl. Organic phase, dried and evaporated under reduced pressure,

afforded **5** as a crude oil that was purified by flash chromatography on silica gel (EtOAc/*n*-hexane 1:1). **5**: Yield 48%; m.p.: 177–178 °C, IR (ν , cm⁻¹): 3324 (NH); ¹H-NMR δ : 7.75–7.08 (m, 6H, Ar), 6.7 (s, 1H, NH), 3.9 (s, 3H, CH₃O), 2.77 (s, 3H, CH₃SO₂); MS: 253 (M+2,1), 252 (M+1, 2), 251 (M⁺, 18), 172 (100); Anal. Calcd. for C₁₂H₁₃NO₃S (251.30) C, 57.35; H, 5.21; N, 5.57%. Found: C, 57.00; H, 5.43; N, 5.28%.

3-Nitro-naphthalene-1-carbonyl chloride (23)

A solution of 3-Nitro-naphthalene-1-carboxylic acid **22**⁸ (3 g, 0.014 mol) in SOCl₂ (18 ml) was refluxed for 3 h. The thionyl chloride was evaporated under reduced pressure, and the solid obtained, triturated with hexane, gave **23** that was purified by crystallization from CCl₄. **23**⁸: Yield 76%; m.p.: 139–140 °C, IR (ν , cm⁻¹): 1751 (C=O); ¹H-NMR δ : 8.88–7.69 (m, 6H, Ar); MS: 235 (M⁺, 0.65), 126 (100).

General procedure for the synthesis of 2 nitro-4-benzoylnaphthalenes (25a-c)

To a suspension of 3-nitro-naphthalene-1-carbonyl chloride 23 (1g, 4.25 mmol) with appropriate benzene derivative 24a-c was added, at 0°C, in 15 minutes, AlCl₃ (851 mg, 6.38 mmol). The reaction mixture was stirred at room temperature for 15 h, then triturated in ice, acidified with 37% HCl to pH = 2 and extracted with Et₂O. The ether phase, washed with 1N NaOH, H₂O, dried and evaporated under reduced pressure, gave the respective 2 nitro-4-benzoyl-naphthalenes 25a-c, which was purified by crystallization from CH₃COCH₃ for compounds 25a and 25b and isopropanol for compound 25c. 25a: Yield 46%; m.p.: 140-143 °C, IR (ν , cm⁻¹): 1665 (C=O); ¹H-NMR δ: 9.10–7.46 (m, 11H, Ar); MS: 277 (M⁺, 20), 105 (100), 77 (70); Anal. Calcd. for C₁₇H₁₁NO₃ (277.27) C, 73.64; H, 4.00; N, 5.05%. Found: C, 73.39; H, 3.81; N, 5.05%. 25b: Yield 54%; m.p.: 146-148 °C, IR (ν , cm⁻¹): 1672 (C=O); ¹H-NMR δ : 8.89– 7.37 (m, 10H, Ar); MS: 311 (M⁺, 20), 139 (100); Anal. Calcd. for C₁₇H₁₀ClNO₃ (311.72) C, 65.50; H, 3.23; N, 4.49%. Found: C, 65.55; H, 3.61; N, 4.75%. 25c: Yield 30%; m.p.: 155–156 °C, IR $(\nu, \text{ cm}^{-1})$: 1672 (C=O); ¹H-NMR δ : 8.90–7.22 (m, 10H, Ar); MS: 356 (M⁺, 34), 185 (98), 126 (100); Anal. Calcd. for C₁₇H₁₀BrNO₃ (356.17) C, 57.33; H, 2.83; N, 3.93%. Found: C, 57.65; H, 2.73; N, 3.66%.

General procedure for the synthesis of 4-benzoyl-2naphthylamines (26a-c)

To a solution of the opportune 2 nitro-4-benzoyl-naphthalenes 25a-c (1.80 mmol) in absolute EtOH (15 ml) was added a catalytic portion of Ni-Raney. The suspension was refluxed and NH₂NH₂ H₂O (0.393 ml, 8.10 mmol) in absolute EtOH (2 ml) was added dropwise. The mixture was refluxed for 1 h compound 26a, 12h compound 26b, 8–10h compound 26c. The suspension was filtered through celite and evaporated under reduced pressure. The residue obtained was dissolved in H₂O, washed with Et₂O and treated with saturated solution of Et₂O/HCl to obtained the opportune amines 26a-c as hydrochloride, which were purified by crystallization from MeOH/Et₂O. 26a: Yield 57%; m.p.: 117 °C, IR (ν, cm^{-1}) : 2613 (NH₂), 1665 (C=O); ¹H-NMR δ : 7.69–7.13 (m, 11H, Ar); MS: 247 (M⁺-HCl, 92), 115 (100), 105 (58), 77 (78); Anal. Calcd. for C₁₇H₁₃NO•HCl (283.75) C, 71.96; H, 4.97; N, 4.94%. Found: C, 71.80; H, 5.25; N, 4.57%. 26b: Yield 45%; m.p.: 144–149 °C, IR (ν , cm⁻¹): 2620 (NH₂), 1672 (C=O); ¹H-NMR δ : 7.95–7.15 (m, 10H, Ar); MS: 281 (M⁺-HCl, 60), 115 (100); Anal. Calcd. for C₁₇H₁₂ClNO[•]HCl (318.20) C, 64.17; H, 4.12; N, 4.40%. Found: C, 54.55; H, 4.46; N, 4.10%. 26c: Yield 40%; m.p.: 119-125 °C, IR (ν , cm⁻¹): 2590 (NH₂), 1675 (C=O); ¹H-NMR

 δ : 8.10–7.35 (m, 10H, Ar); MS: 325 (M⁺-HCl, 38), 115 (100); Anal. Calcd. for C₁₇H₁₂BrNO•HCl (362.65) C, 56.30; H, 3.61; N, 3.86%. Found: C, 56.58; H, 3.75; N, 3.51%.

N-(4-benzoyl-2-naphthyl)-methanesulfonamides (6a-c)

The sulfonamides 6a-c were synthesized from 4-benzoyl-2naphthylamines 26a-c as previously reported for compound 5 and were purified by crystallization from Et₂O/hexane, CHCl₃/Et₂O and AcOEt/hexane respectively. 6a: Yield 51%; m.p.: 48 °C, IR $(\nu, \text{ cm}^{-1})$: 3270 (NH), 1657 (C=O); ¹H-NMR δ : 7.86–7.34 (m, 11H, Ar), 7.11 (s, 1H, NH), 3.04 (s, 3H, CH₃SO₂); MS: 327 (M+2, 8), 326 (M+1, 15), 325 (M⁺, 50), 77 (100); Anal. Calcd. for C₁₈H₁₅NO₃S (325.38) C, 66.44; H, 4.65; N, 4.30%. Found: C, 66.54; H, 4.87; N, 4.21%. 6b: Yield 40%; m.p.: 135-136 °C, IR $(\nu, \text{ cm}^{-1})$: 3269 (NH), 1657 (C=O); ¹H-NMR δ ppm 7.81–7.23 (m, 10H, Ar), 7.11 (s, 1H, NH), 3.06 (s, 3H, CH₃SO₂); MS: 361 (M+2, 22), 360 (M+1, 10), 359 (M⁺, 58), 111 (100), 75 (65); Anal. Calcd. for C₁₈H₁₄ClNO₃S (359.04) C, 60.08; H, 3.92; N, 3.89%. Found: C, 59.78; H, 3.49; N, 3.47%. 6c: Yield 35%; m.p.: 105–115 °C, IR (ν , cm⁻¹): 3278 (NH), 1659 (C=O); ¹H-NMR δ : 7.84-7.22 (m, 10H, Ar), 3.03 (s, 3H, CH₃SO₂); MS: 406 (M+2, 5), 405 (M+1, 25), 404 (M⁺, 40), 183 (100); Anal. Calcd. for C₁₈H₁₄BrNO₃S (404.28) C, 53.48; H, 3.49; N, 3.46%. Found: C, 53.37; H, 3.36; N, 3.22%.

6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine (28)

A solution of 6-Methoxy-3,4-dihydro-[1,2]-naphthoquinone-2oxime 27 (1 g, 4.9 mmol) in MeOH (50 ml) and HCl 10% (9 ml) was hydrogenated at 50 °C at 1 atm in the presence of Pd/C (500 mg). After 20 h the catalyst was reactivated and the hydrogenation continued for another 20 h. The reaction mixture was filtrated and evaporated under reduced pressure. The crude residue crystallized from EtOH furnished the desired hydrochloride derivative 28. The hydrochloride salt of 28 was converted into the free base by treating an aqueous solution of the salt with solid KOH, then extracting the free bases with CHCl₃. The organic layer washed (H₂O) filtered and evaporated gave 28 as a solid. 28: Yield 60%; m.p.: 230-240 °C, IR $(\nu, \text{ cm}^{-1})$: 3146, 2621 (NH₂); ¹H-NMR δ : 7.22–6.59 (m, 3H, Ar), 3.75 (s, 3H, CH₃O), 2.91-2.76 (m, 3H, aliphatic), 1.56-1.26 (m, 4H, aliphatic); MS: 177 (M⁺, 0.89), 174 (82); Anal. Calcd. for C₁₁H₁₅NO (177.24) C, 74.54; H, 8.53; N, 7.90%. Found: C, 74.25; H, 8.86; N, 7.61%.

7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine (29)

To a solution of 7-Methoxy-3,4-dihydro-1H-naphthalen-2-one 30 (500 mg, 2.84 mmol) in anhydrous MeOH (15 ml) was added CH₃COONH₄ (2.19 g, 28.4 mmol) and NaBH₃CN (125 mg, 199 mmol). The mixture was stirred for 48 h, then acidified with HCl (37%) to pH < 2, evaporated under reduced pressure. The residue was dissolved in H₂O, washed with Et₂O, alkalized and extracted with Et₂O. The ether phase, dried and evaporated under reduce pressure, gave 7-Methoxy-1,2,3,4-tetrahydronaphthalen-2-ylamine 29 which, in the presence of Et₂O/HCl was transformed into the corresponding hydrochloride. The hydrochloride salt of 29 was converted into the free base by treating an aqueous solution of the salt with solid KOH then extracting the free base with CHCl3. The organic layer was washed (H_2O) filtered and evaporated to give 29 as a solid. 29: Yield 52%; m.p.: 220-225 °C, IR (ν , cm⁻¹): 3490, 2930 (NH₂); ¹H-NMR (δ ppm): 7.22–6.58 (m, 3H, Ar), 3.75 (s, 3H, CH₃O), 2.91-2.76 (m, 3H, aliphatic), 1.57-1.25 (m, 4H, aliphatic); MS: 177 (M⁺, 0.79), 174 (82); Anal. Calcd. for C₁₁H₁₅NO (177.24) C, 74.54; H, 8.53; N, 7.90%. Found: C, 74.98; H, 8.90; N, 7.55%.

412 S. Nencetti et al.

N-(6-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)methanesulfonamide (7) N-(7-Methoxy-1,2,3,4tetrahydro-naphthalen-2-yl)-methanesulfonamide (8)

Sulfonamides compounds 7 and 8 were synthesized from compounds 28 and 29 as previously reported for 1 and 2. Compounds 7, 8 were purified by crystallization from CH₂Cl₂/ hexane and CH₃COCH₃/hexane, respectively. 7: Yield 20%; m.p.: 132–134 °C, IR (ν , cm⁻¹): 3268 (NH); ¹H-NMR δ : 6.36–6.71 (m, 3H, Ar), 4.43 (bs, 1H, NH), 3.71 (s, 3H, CH₃O), 2.97 (s, 3H, CH₃SO₂), 3.04–2.55 (m, 4H, aliphatic), 2.56–2.12 (m, 3H, aliphatic); MS: 257 (M+2, 0.87), 256 (M+1, 1.76), 255 (M⁺, 12), 160 (100); Anal. Calcd. C12H17NO3S (255.33) C, 56.45; H, 6.71; N, 5.49%. Found: C, 56.76; H, 6.78; N, 5.21%. 8: Yield 51%; m.p.: 101–108 °C, IR (ν , cm⁻¹): 3261 (NH); ¹H-NMR δ : 6.91-6.56 (m, 3H, Ar), 4.5 (bs, 1H, NH), 3.74 (s, 3H, CH₃O), 2.98 (s, 3H, CH₃SO₂), 3.06-2.75 (m, 4H, aliphatic), 2.02 (m, 3H, aliphatic); MS: 257 (M+2, 1), 256 (M+1, 2), 255 (M⁺, 10), 160 (100); Anal. Calcd. C₁₂H₁₇NO₃S (255.33) C, 56.45; H, 6.71; N, 5.49%. Found: C, 56.13; H, 6.92; N, 5.28%

Enzyme assays

Compounds 1–4, 6a,b and 7 were tested following the procedure previously described⁹ in intact cell assays to verify their capacity to inhibit PGE2 production, considered as an index of activity on COX-1 and COX-2.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

References

- Suraneni MV, Reddy GV, Pallu R. NSAIDs, COXIBs, CLOXIBs and cancer pain. Horizons Cancer Res 2012;47:253–70.
- Townsed KP, Patrico D. Novel therapeutic opportunities for Alheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005;19:1592–601.
- Nivsarkar M, Banerjee A, Padh H. Cyclooxygenase inhibitor: a novel direction for Alzheimer's management. Pharmacol Rep 2008;60:692–8.
- Narsinghani T, Sharma R. Lead optimization on conventional nonsteroidal anti-inflammatory drugs: an approach to reduce gastrointestinal toxicity. Chem Biol Drug Des 2014. [Epub ahead of print]. doi: 10.1111/cbdd.12292:1-23.
- Spahn H, Langguth P. chiral amines derived from 2-arylpropionic acids: novel reagents for the liquid chromatography (LC) fluorescence assay of optically active carboxylic xenobiotics. Pharm Res 1990;7:1262–8.
- Matsunaga N, Kaku T, Akio O, et al. C17, 20-lyase inhibitors. Part 2: Design, synthesis and structure – activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C17,20-lyase inhibitors. Bioorg Med Chem 2004;12:4313–36.
- MacMillan JB, Xiong-Zhou G, Skepper CK, Molinski TF. Phorbasides A-E, cytotoxic chlorocyclopropane macrolide glycosides from the marine sponge *Phorbas* sp. CD determination of c-methyl sugar configurations. J Org Chem 2008;73: 3699–706.
- 8. Lee J.-J, Noll BC, Smith BD. Fluorescent chemosensor for chloroalkanes. Org Lett 2008;10:1735–8.
- Balsamo A, Coletta I, Domiano P, et al. Synthesis and COX-2 inhibitiory properties on N-Phenyl-and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and their pyrazole, thiophene and isoxazole analogs. Eur J Med Chem 2002;37:391–8.